Search Results - Amarapala, Miyuru

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis

    A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis by Jalaleddini, Kian, Bermel, Robert A, Talente, Bari, Weinstein, David, Qureshi, Ferhan, Rasmussen, Maital, Menon, Sreeranjani, Amarapala, Miyuru, Jordan, Kesshi, Ghoreyshi, Ati, McCurdy, Shannon, Edgeworth, Mike

    Published in Multiple sclerosis
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

    Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United State... by Kilcoyne, Adrian, Jordan, Edward, Zhou, Allen, Thomas, Kimberly, Pepper, Alicia N., Chappell, Dale, Amarapala, Miyuru, Hughes, Avery, Thompson, Melissa

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19

    Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 by Amarapala, Miyuru, Chappell, Dale, Pepper, Alicia N, Kilcoyne, Adrian, Theriault, Rachel-Karson, Thompson, Melissa, Zhou, Allen, Jordan, Edward, Thomas, Kimberly

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England

    Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVI... by Kilcoyne, Adrian, Jordan, Edward, Thomas, Kimberly, Pepper, Alicia N, Zhou, Allen, Chappell, Dale, Amarapala, Miyuru, Thériault, Rachel-Karson, Thompson, Melissa

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: